View Older Stories View More Recent Stories
-
DexCom (DXCM) options active on 24K contracts
-
DexCom CEO takes medical leave, COO named interim leader
-
Piper Sandler on calls with diabetes clinicians
-
Oppenheimer Downgrades DexCom (DXCM) to Perform
-
Piper Sandler on DexCom (DXCM): 'NIT2 Should More Than Offset; The Stock Should Be Owned Here'
-
DexCom (DXCM) Shares Active, Conf. Ongoing
-
Argus Starts DexCom (DXCM) at Buy
-
DexCom (DXCM) PT Raised to $106 at UBS
-
DexCom (DXCM) Tops Q2 EPS by 3c; offers guidance
-
DexCom adds AI meal logging to Stelo and G7 glucose monitors
-
Dexcom (DXCM) Removes Certain Dexcom G6, G7, ONE, and ONE+ Receivers Due to Speaker Malfunction
-
BTIG names top large-cap picks for second half of 2025
-
Oppenheimer Reiterates Outperform Rating on DexCom (DXCM)
-
DexCom (DXCM) Gains Amid Chatter of HHS Push for Wearable Tech
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
Truist Securities Starts DexCom (DXCM) at Buy
-
Piper Sandler Highlights DexCom (DXCM) Stock Following Educator Survey
-
Goldman Sachs Starts DexCom (DXCM) at Buy
-
RBC Capital on DexCom (DXCM): 'Valuation Signals Opportunity'
-
DexCom (DXCM) Appoints Jacob S. Leach as COO
-
DexCom (DXCM) PT Raised to $106 at Canaccord Genuity
-
DexCom (DXCM) PT Lowered to $88 at Bernstein SocGen Group
-
DexCom (DXCM) PT Raised to $109 at BTIG
-
DexCom (DXCM) Misses Q1 EPS by 1c; offers guidance
-
Bernstein Reiterates Outperform Rating on DexCom (DXCM) Following FDA Approval
-
Canaccord Genuity Reiterates Buy Rating on DexCom (DXCM)
-
Raymond James Reiterates Strong Buy Rating on DexCom (DXCM), PT $99, 'we believe the stock should be strong today'
-
Stifel Reiterates Buy Rating on DexCom (DXCM)
-
BTIG Reiterates Buy Rating on DexCom (DXCM)
-
DexCom (DXCM) G7 15 Day Receives FDA Clearance
-
Mizuho Starts DexCom (DXCM) at Outperform
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
DexCom (DXCM) Appoints Jon Coleman as CCO
-
Citi Reiterates Buy Rating on DexCom (DXCM)
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
DexCom (DXCM) Appoints Renée Galá to its Board
-
BTIG Reiterates Buy Rating on DexCom (DXCM)
-
This stock has 'multiple drivers of upside for 2025': analyst
-
Bernstein on DexCom (DXCM): 'Back on Track in 2025?'; PT Raised to $100
-
DexCom (DXCM) Misses Q4 EPS by 7c ; Offers Guidance
-
BofA on DexCom (DXCM): 'a particularly attractive buying opportunity'
-
Redburn-Atlantic Upgrades DexCom (DXCM) to Buy
-
Raymond James Reiterates Strong Buy Rating on DexCom (DXCM)
-
Piper Sandler on DexCom (DXCM): 'We Believe it is Time for Investors to Come Back to the Name'
-
Baird Upgrades DexCom (DXCM) to Outperform
-
Citi Reiterates Buy Rating on DexCom (DXCM)
-
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
4 MedTech stocks to own for 2025: BTIG

